Australian digital health group Adherium will start selling smart inhalers to pharmaceutical makers in a move that has been backed by pharma giant AstraZeneca
Adherium plans to sell the trademarked Smartinhaler platform directly to pharmaceutical companies, who then provide the device and supporting applications to end users via their own distribution channels.
The company already currently supplies its Smartinhaler platform to disease management organisations and organisations conducting clinical trials.
Clinical studies have shown that the Smartinhaler increases medication adherence by up to 59% in adults and 180% in children. In addition, use of Smartinhaler resulted in a 60% reduction in severe attacks in adults.
The Smartinhaler recently raised sufficient funds from investors to allow Adherium to manufacture at commercial quantities.
In addition the firm has signed long term supply and development agreement with global biopharmaceutical company AstraZeneca.
Adherium Group Chief Executive Officer Garth Sutherland said, “I am thrilled with the overwhelming investor support ranging from international institutional investors through to small retail investors. The Adherium team is committed to providing market-leading digital health solutions that have a real and meaningful impact for people with chronic disease. We believe our proven ability to innovate and deliver will ensure we generate ongoing value for our shareholders.”